Costs of allogeneic hematopoietic stem cell transplantation

Transplantation

Volumn 82, Issue 2, 2006, Pages 147-153

  Svahn, Britt Marie ^a   Alvin, Ole ^a   Ringdén, Olle ^a   Gardulf, Ann ^a   Remberger, Mats ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allogeneic stem cell transplantation; Costs; Health economics; Home care

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; BUSULFAN; CARBOPLATIN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; CYTOSTATIC AGENT; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IFOSFAMIDE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BACTEREMIA; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COST BENEFIT ANALYSIS; FEMALE; FEVER; GRAFT INFECTION; HAZARD ASSESSMENT; HEALTH CARE COST; HEMORRHAGIC CYSTITIS; HERPES SIMPLEX; HOME CARE; HOSPITAL ADMISSION; HOSPITAL CARE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER VEIN OBSTRUCTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; OUTPATIENT; PANCYTOPENIA; PNEUMOCYSTOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; REDUCED INTENSITY CONDITIONING; REIMBURSEMENT; RETRANSPLANTATION; SOLID TUMOR; SURVIVAL RATE; WHOLE BODY RADIATION;

COST OF ILLNESS; FOLLOW-UP STUDIES; HUMANS; INFECTION; INPATIENTS; NEOPLASMS; OUTPATIENTS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; SWEDEN; TRANSPLANTATION, HOMOLOGOUS;

EID: 33746445838     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000226171.43943.d3     Document Type: Article

References (32)

1. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511.
2. Storb R, Doney KC, Thomas ED, et al. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood 1982; 59: 236.
3. Ringdén O. Allogeneic bone marrow transplantation for hematological malignancies - controversies and recent advances. Acta Oncologica 1997; 36: 549.
4. Peters C, Steward C. Haematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practic guidelines. Bone Marrow Transplant 2003; 31: 229.
5. Department of Health and Human Services. Hospital Prospective Payment for Medicare: Report to Congress. Baltimore, MD; December 1982.
6. Dufoir T, Saux MC, Terraza B, et al. Comparative cost at allogenic or autologous bone marrow transplantation and chemotherapu in patients with acute myeloid leukaemia in first remission. Bone Marrow Transplant 1992; 10: 323.
7. Barr R, Furlong W, Henwood I, et al. Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formlation of clinical policy. J Clin Oncol 1996; 14: 1413.
8. Lee SI, Anasetti C, Kuntz KM, et al. The cost and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukaemia. Blood 1998; 92: 4047.
9. Lee SJ, Klar N, Weeks JC, Antin JH. Predicting costs of stem cell transplantation. J Clin Oncol 2000; 18: 64.
10. Mishra V, Vaaler S, Brinch L. A prospective cost evaluation related to allogeneic haematopoietic stem cell transplantation including pretransplant procedures, transplantation and 1-year follow-up procedures. Bone Marrow Transplant2001; 28: 1111.
11. Ringdén O, Remberger M, Ruutu T, et al., for the Nordic Bone Marrow Transplantation Group. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis and alopecia using busultan compared to total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Blood 1999; 93: 2196.
12. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729.
13. Ringdén O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993; 81: 1094.
14. Ringdén O, Remberger M, Aschan J, et al. Long-term follow-up of a randomized trial comparing T-cell-depletion with a combination of methotrexate and cyclosporin in adult leukemic marrow transplant recipients. Transplantation 1994; 58: 887.
15. Remberger M, Svahn B-M, Hentschke P, et al. Effect on cytokine release and graft-versus-host disease of different anti-T-cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823.
16. Svahn B-M, Remberger M, Myrbäck K-E, et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared to hospital care. Blood 2002; 100: 4317.
17. Remberger M, Naseh N, Aschan J, et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant 2003; 32: 217.
18. Ringdén O, Labopin M, Gorin N-C, et al., for the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukaemia increases the risk ot graft-versus-host disease and death. J Clin Oncol 2004; 22: 416.
19. McSweeney P, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999; 5: 192.
20. Hentschke P, Barkholt L, Uzunel M, et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003; 31: 253.
21. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756.
22. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550.
23. Sparrelid E, Hägglund H, Remberger M, et al. Risk factors for septicemia during aplastic period after allogeneic bone marrow transplantation. Transplant Proc 1995; 27: 3530.
24. Ringdén O, Remberger M, Persson U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619.
25. Ruutu T, Eriksson B, Remes K, et al., for the Nordic Bone Marrow Transplantation Group. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977.
26. Abecasis MM, Conceicao Silva JP, Ferreira I, et al. Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 843.
27. Chalandon Y, Roosnek E, Mermillod B, et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 347.
28. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337.
29. Ringdén O, Remberger M, Lehmann S, et al. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 25: 993.
30. Prentice HG, Blacklock HAA, Janossy G, et al. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1984; i: 472.
31. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120.
32. de Lissovoy G, Hurd D, Carter S, et al. Economic analysis of unrelated allogeneic bone marrow transplantation: results from the randomized clinical trial of T-Cell depletion vs unmanipulated grafts for the prevention of graft-versus-host disease. Bone Marrow Transplant 2005; 36: 539.